Bellicum Pharmaceuticals库存 uauniez

Bellicum Pharmaceuticals库存

30.12.2020

Bverger7451

HOUSTON, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it is offering to sell, subject to market and other conditions, shares of its Series 1 preferred stock and warrants to purchase shares of its common stock in a public Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) issued its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.73) by $3.82. Bellicum Pharmaceuticals had a negative return on equity of 664.19% and a negative net margin of 1,574.65%. Jan 18, 2020. Bellicum Pharma (BLCM) Up 140% In A Month, To Report BPX-601 Data On Jan.24 . Dec 11, 2019. Health Care Sector Update for 12/11/2019: BLCM,SAGE,GENE,RCKT Bellicum Pharmaceuticals Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, sowie aktuelle Nachrichten und Meinungen.

作者：deer2005 发表时间：2020-01-20 更新时间：2020-01-20 浏览：1774次评论：113篇地址：174.

BLCM | Complete Bellicum Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. 提供Bellicum Pharmaceuticals Inc(BLCM)股票的行情走势、五档盘口、逐笔交易等实时行情数据，及Bellicum Pharmaceuticals Inc(BLCM)的资讯、公司公告、研究报告、行业研报、F10资料、行业资讯、资金流分析、阶段涨幅、所属板块、财务指标、机构观点、行业排名、估值水平、股吧互动等与Bellicum Pharmaceuticals Inc(BLCM HOUSTON, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it is offering to sell, subject to market and other conditions, shares of its Series 1 preferred stock and warrants to purchase shares of its common stock in a public Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) issued its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.73) by $3.82. Bellicum Pharmaceuticals had a negative return on equity of 664.19% and a negative net margin of 1,574.65%.

BELLICUM PHARMACEUTICALS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Bellicum Pharmaceuticals Inc | A12GT1 | BLCM | US0794811077

重磅!易会满详解资本市场改革方向和举措：改革将从科创板"试验田"稳步推向全市场12:37 大消息!易会满周末重磅发声作者：deer2005 发表时间：2020-01-20 更新时间：2020-01-20 浏览：1774次评论：113篇地址：174. Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program. HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication of preclinical data Read more >

BLCM | Complete Bellicum Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Bellicum制药的新闻 Bellicum制药2018财年第二财季净利-2417.50万美元同比增加1.15% 08月08日 18:38. 8月7日Bellicum制药(股票代码：BLCM)公布财报，公告显示公司2018财年第二财季净利润为-2417.50万美元，同比增长1.15%；营业收入为36.20万美元， Bellicum制药公司于2004年7月在特拉华州成立 Bellicum Houston Life Science Plaza 2130 West Holcombe Boulevard, Suite 800 Houston, Texas 77030 (832) 384-1100. Bellicum South San Francisco 611 Gateway Boulevard, Suite 820 South San Francisco, California 94080 (628) 251-5050. For Investor relations inquiries, please contact robert.uhl@westwicke.com. For Media

作者：deer2005 发表时间：2020-01-20 更新时间：2020-01-20 浏览：1774次评论：113篇地址：174.

Bellicum Pharmaceuticals, Inc. Biotechnology Houston, TX 6,989 followers Bellicum is a clinical-stage biopharmaceutical company that is driving the future of celluar IO. Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy). Simply Wall St.